CoChat

Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice

Nishio, Takahiro, Hu, Ronglin, Koyama, Yukinori, Liang, Shuang, Rosenthal, Sara B., Yamamoto, Gen, Karin, Daniel, Baglieri, Jacopo, Ma, Hsiao-Yen, Xu, Jun, Liu, Xiao, Dhar, Debanjan, Iwaisako, Keiko, Taura, Kojiro, Brenner, David A., Kisseleva, Tatiana · 2019 · Journal of Hepatology
Cited by 135

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND AIMS Chronic liver injury often results in activation of hepatic myofibroblasts and development of liver fibrosis. Hepatic myofibroblasts may originate from three major sources; Hepatic Stellate Cells (HSCs), Portal Fibroblasts (PFs), or fibrocytes. Their contribution to liver fibrosis varies dependent on the etiology of liver injury. Here we assessed the composition of hepatic myofibroblasts in multidrug resistance gene 2 knockout (Mdr2-/-) mice, a genetic model that resembles primary sclerosing cholangitis in patients. METHODS Mdr2-/- mice expressing a collagen-GFP reporter were analyzed at different ages. Hepatic nonparenchymal cells isolated from collagen-GFP Mdr2-/- mice were sorted based on collagen-GFP and vitamin A. A nicotinamide adenine dinucleotide phosphate oxidase (NOX) 1/4 inhibitor was administrated to Mdr2-/- mice during ages 12- to 16-weeks-old to assess the therapeutic approach targeting oxidative stress in cholestatic injury. RESULTS Thy1+ activated PFs (aPFs) accounted for 26%, 51%, and 54% of collagen-GFP+ myofibroblasts in Mdr2-/- mice at 4 weeks, 8 weeks, and 16 weeks of age, respectively. The remaining collagen-GFP+ myofibroblasts were composed of activated HSCs (aHSCs), suggesting that PFs and HSCs are both activated in Mdr2-/- mice. BM-derived fibrocytes minimally contributed to liver fibrosis in Mdr2-/- mice. Development of cholestatic liver fibrosis in Mdr2-/- mice was associated with early recruitment of Gr1+ myeloid cells and upregulation of pro-inflammatory cytokines (4 weeks). Administration of a NOX inhibitor to 12-week-old Mdr2-/- mice suppressed activation of myofibroblasts and attenuated development of cholestatic fibrosis. CONCLUSIONS aPFs and aHSCs contribute to cholestatic fibrosis in Mdr2-/- mice, and serve as targets for anti-fibrotic therapy. LAY SUMMARY Activated Portal Fibroblasts and Hepatic Stellate Cells, but not fibrocytes, contributed to the production of the fibrous scar in livers of Mdr2-/- mice, and these cells can serve as targets for anti-fibrotic therapy in cholestatic injury. Therapeutic inhibition of the enzyme nicotinamide adenine dinucleotide phosphate oxidase (NOX) in Mdr2-/- mice reversed cholestatic fibrosis, suggesting that targeting of NOXs can provide a novel strategy for treatment of cholestatic fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2019.04.012

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 135

Metadata

Authors
Nishio, T., Hu, R., Koyama, Y., Liang, S., Rosenthal, S. B., Yamamoto, G., Karin, D., Baglieri, J., Ma, H.-Y., Xu, J., Liu, X., Dhar, D., Iwaisako, K., Taura, K., Brenner, D. A., & Kisseleva, T.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2019-09
Volume
71
Issue
3
Pages
573-585
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2943334785
Cited by
135
References
12
FWCI
8.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.